|Bid||4.63 x 800|
|Ask||4.88 x 1000|
|Day's Range||4.5600 - 4.8800|
|52 Week Range||2.6380 - 5.7390|
|Beta (3Y Monthly)||1.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 1, 2019 - Apr 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designations (ODD) to Cerecor’s three substrate replacement therapies for Congenital Disorders of Glycosylation (CDGs). Each indication is an ultra-rare CDG estimated to have fewer than 1,000 patients in the United States.
Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors. Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders. He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.
On October 31, 2018, Cerecor, Inc. (CERC) announced the submission of three Orphan Drug Designation (ODD) requests for three of the development products acquired from the purchase of Ichorion Therapeutics, Inc. Each of them is being developed for the treatment of ultrarare metabolic disorders known as Inborn Errors of Metabolism (IEM). CERC-801 (D-galactose): This is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, a recently characterized congenital disorder of glycosylation (CDG). The multisystem deficiencies are a result of a lack of protein glycosylation, which is dependent upon the important metabolic intermediate glucose-1-phosphate.
If you own shares in Cerecor Inc (NASDAQ:CERC) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
BALTIMORE, Nov. 13, 2018 -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and.
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has submitted to the U.S. Food and Drug Administration (FDA) three Orphan Drug Designation (ODD) Requests for substrate replacement therapies to treat ultra-rare inherited metabolic disorders known as Congenital Disorders of Glycosylation (CDGs). Each indication is an ultra-rare CDG estimated to have less than 1,000 patients in the United States.
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has been awarded Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for CERC-801. CERC-801 is a substrate replacement therapy to treat an ultra-rare inherited metabolic disorder known as an Inborn Error of Metabolism (IEM).
Cerecor, Inc. (CERC) is a fully integrated pharmaceutical company with a diversified offering of commercial products and a development product portfolio. On September 25, 2018, Cerecor announced the acquisition of privately-held Ichorion Therapeutics, Inc., a biotechnology company focused on ultra-rare orphan diseases caused by inborn errors of metabolism (IEM). In addition, Ichorion has a platform to target IEMs that are not amenable to substrate replacement therapy.
The acquisition fits with Cerecor's recent transition to a greater focus on bringing pediatric therapeutics to market.
Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.
Cerecor, Inc. (CERC) is a fully integrated pharmaceutical company with a diversified offering of commercial products and a development product portfolio. The company’s goal is to use cash flow from commercial operations to fund the development of the clinical product candidates. The company recorded net revenues of $4.8 million in the second quarter of 2018 compared to $0.2 million in the second quarter of 2017.
Penny stock pickers booked modest returns in these tough conditions, while trend followers and dart throwers took losses. The July penny stock list generated mixed returns, with precious metals and biotech headwinds limiting gains while a mid-month crude oil reversal undermined small energy plays.
Undervalued companies are those that trade at a price lower than their actual values, such as Cerecor and China Yuchai International. There’s a few ways you can determine how muchRead More...
Following disappointing clinical trial results in 2016 and 2017, the company has pivoted to a new strategy through the acquisition of TRx Pharmaceuticals and the pediatric products from Avadel U.S. Holdings, Inc. While details of the company’s strategy are still coming together, in 2018 we believe investors should focus on the ability of management to continue growing the commercial side of the business, maintain business development activity, and advance the development pipeline. As the year progresses, we believe the company will provide additional details concerning all of those areas. The acquisition signifies Cerecor’s move to a pediatric-focused healthcare company and is being undertaken to provide a source of revenue to help fund the company’s development pipeline.